File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/eye.1999.5
- Scopus: eid_2-s2.0-0033035479
- PMID: 10396379
- WOS: WOS:000079097300005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Limited argon laser peripheral iridoplasty as immediate treatment for an acute attack of primary angle closure glaucoma: A preliminary study
Title | Limited argon laser peripheral iridoplasty as immediate treatment for an acute attack of primary angle closure glaucoma: A preliminary study |
---|---|
Authors | |
Keywords | Acute angle closure glaucoma Laser peripheral iridoplasty |
Issue Date | 1999 |
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/eye |
Citation | Eye, 1999, v. 13 n. 1, p. 26-30 How to Cite? |
Abstract | Purpose. To study the efficacy and safety of limited (180°) argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle closure glaucoma (PACG) without the use of systemic anti-glaucomatous medications. Methods. Ten consecutive patients with PACG were recruited into the study. Each patient received topical pilocarpine (4%) and timolol (0.5%), and immediate limited ALPI as primary treatment. The intraocular pressures at 15, 30 and 60 min after ALPI were documented by Goldmann applanation tonometry. Results. The mean intraocular pressure (IOP) of this group of patients was reduced from 57.9 ± 10.6 mmHg to 39.0 ± 10.9 mmHg at 15 min, 28.3 ± 9.1 mmHg at 30 min and 20.4 ± 9.0 mmHg at 60 min after ALPI. No complications were encountered. In 8 of the 10 patients the corneal oedema cleared 1 h after ALPI. In the remaining 2 patients the corneal oedema cleared 2 h after ALPI. Conclusion. Immediate limited ALPI, without adjunctive systemic anti-glaucomatous medications, appeared to be effective and safe in controlling the IOP in treating acute PACG with a duration of attack ≤ 48 h. It may be as effective as 360°ALPI, and therefore has a role in those patients in whom 360°treatment is not possible. |
Persistent Identifier | http://hdl.handle.net/10722/176357 |
ISSN | 2023 Impact Factor: 2.8 2023 SCImago Journal Rankings: 1.373 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lai, JSM | en_US |
dc.contributor.author | Tham, CCY | en_US |
dc.contributor.author | Lam, DSC | en_US |
dc.date.accessioned | 2012-11-26T09:10:47Z | - |
dc.date.available | 2012-11-26T09:10:47Z | - |
dc.date.issued | 1999 | en_US |
dc.identifier.citation | Eye, 1999, v. 13 n. 1, p. 26-30 | en_US |
dc.identifier.issn | 0950-222X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/176357 | - |
dc.description.abstract | Purpose. To study the efficacy and safety of limited (180°) argon laser peripheral iridoplasty (ALPI) as a first-line treatment for acute primary angle closure glaucoma (PACG) without the use of systemic anti-glaucomatous medications. Methods. Ten consecutive patients with PACG were recruited into the study. Each patient received topical pilocarpine (4%) and timolol (0.5%), and immediate limited ALPI as primary treatment. The intraocular pressures at 15, 30 and 60 min after ALPI were documented by Goldmann applanation tonometry. Results. The mean intraocular pressure (IOP) of this group of patients was reduced from 57.9 ± 10.6 mmHg to 39.0 ± 10.9 mmHg at 15 min, 28.3 ± 9.1 mmHg at 30 min and 20.4 ± 9.0 mmHg at 60 min after ALPI. No complications were encountered. In 8 of the 10 patients the corneal oedema cleared 1 h after ALPI. In the remaining 2 patients the corneal oedema cleared 2 h after ALPI. Conclusion. Immediate limited ALPI, without adjunctive systemic anti-glaucomatous medications, appeared to be effective and safe in controlling the IOP in treating acute PACG with a duration of attack ≤ 48 h. It may be as effective as 360°ALPI, and therefore has a role in those patients in whom 360°treatment is not possible. | en_US |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/eye | en_US |
dc.relation.ispartof | Eye | en_US |
dc.subject | Acute angle closure glaucoma | - |
dc.subject | Laser peripheral iridoplasty | - |
dc.subject.mesh | Acute Disease | en_US |
dc.subject.mesh | Adrenergic Beta-Antagonists - Therapeutic Use | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 And Over | en_US |
dc.subject.mesh | Combined Modality Therapy | en_US |
dc.subject.mesh | Drug Therapy, Combination | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Glaucoma, Angle-Closure - Drug Therapy - Surgery | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Iris - Surgery | en_US |
dc.subject.mesh | Laser Therapy - Methods | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Parasympathomimetics - Therapeutic Use | en_US |
dc.subject.mesh | Pilocarpine - Therapeutic Use | en_US |
dc.subject.mesh | Preanesthetic Medication | en_US |
dc.subject.mesh | Time Factors | en_US |
dc.subject.mesh | Timolol - Therapeutic Use | en_US |
dc.title | Limited argon laser peripheral iridoplasty as immediate treatment for an acute attack of primary angle closure glaucoma: A preliminary study | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lai, JSM: laism@hku.hk | en_US |
dc.identifier.authority | Lai, JSM=rp00295 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1038/eye.1999.5 | - |
dc.identifier.pmid | 10396379 | - |
dc.identifier.scopus | eid_2-s2.0-0033035479 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0033035479&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 13 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 26 | en_US |
dc.identifier.epage | 30 | en_US |
dc.identifier.isi | WOS:000079097300005 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Lai, JSM=7401939748 | en_US |
dc.identifier.scopusauthorid | Tham, CCY=7006081241 | en_US |
dc.identifier.scopusauthorid | Lam, DSC=35500200200 | en_US |
dc.identifier.issnl | 0950-222X | - |